KRAS and non-small cell lung carcinoma: Promising evidence has demonstrated that adagrasib plus pembrolizumab improves overall response rate in patients with newly diagnosed NSCLC harboring a KRAS G12C mutation, particularly in those with higher levels of PD-L1 (115).